Cyltezo(adalimumab-adbm), the First Interchangeable Biosimilar to Humira
The US FDA has approved the first interchangeable biosimilar product to treat…
RINVOQ™ (Upadacitinib), approved for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
The European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an…
European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today…